|
|
|
|
LEADER |
00000cam a2200000Mi 4500 |
001 |
EBOOKCENTRAL_ocn796383250 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
120625s2012 xx o 000 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCO
|d N$T
|d OCLCQ
|d YDXCP
|d OCLCQ
|d DEBSZ
|d OCLCQ
|d ZCU
|d MERUC
|d GRG
|d OCLCF
|d ICG
|d AU@
|d OCLCQ
|d DKC
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
019 |
|
|
|a 1058001592
|
020 |
|
|
|a 9783527652938
|q (electronic bk.)
|
020 |
|
|
|a 3527652930
|q (electronic bk.)
|
029 |
1 |
|
|a AU@
|b 000055816182
|
029 |
1 |
|
|a DEBBG
|b BV042794946
|
029 |
1 |
|
|a DEBBG
|b BV044166376
|
029 |
1 |
|
|a DEBSZ
|b 431152527
|
029 |
1 |
|
|a DEBSZ
|b 449306089
|
029 |
1 |
|
|a AU@
|b 000073064531
|
035 |
|
|
|a (OCoLC)796383250
|z (OCoLC)1058001592
|
050 |
|
4 |
|a RC119.7
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.792
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Parasitic helminths :
|b targets, screens, drugs, and vaccines /
|c edited by Conor R. Caffrey.
|
260 |
|
|
|a Hoboken :
|b John Wiley & Sons,
|c 2012.
|
300 |
|
|
|a 1 online resource (542 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Drug Discovery in Infectious Diseases
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Parasitic Helminths: Targets, Screens, Drugs and Vaccines; Foreword to Parasitic Helminths: Targets, Screens, Drugs and Vaccines; Contents; Preface; List of Contributors; Part One: Targets; 1 Ligand-Gated Ion Channels as Targets for Anthelmintic Drugs: Past, Current, and Future Perspectives; Introduction; Established LGIC Anthelmintic Drug Targets; GluCls -- Targets for Ivermectin; L-Type nAChRs -Targets for Levamisole, Pyrantel, Morantel, and Tribendimidine; nAChRs (DEG-3 Group) -- Targets for AADs; GABA-Gated Chloride Channels -- Targets for Piperazine.
|
505 |
8 |
|
|a Evaluating Possible Anthelmintic Targets for the FutureN-Type nAChRs; Nematode-Specific nAChRs and Orphan nAChR-Like Subunits; GABA Receptor Cation Channels; 5-HT Channels; ACh Chloride Channels; GGR-1 Group; GGR-3 Group; LGC-45 Group; Ungrouped Subunits; Cys-Loop LGIC Superfamilies of Other Nematodes; Genomics; Chemistry-to-Gene Screens to Identify New Targets; First Crystal Structure of a Cys-Loop LGIC Complexed with a Commercial Animal Health Drug; Conclusions and Future Lines of Research; References.
|
505 |
8 |
|
|a 2 How Relevant is Caenorhabditis elegans as a Model for the Analysis of Parasitic Nematode Biology?; Introduction; Comparative Genome Analysis for the Phylum Nematoda; Functional Characterization of Parasite Genes by Heterologous Expression in C. elegans; Comparative Pharmacology of C. elegans and Parasitic Nematode Neurotransmitter Receptors; C. elegans as a Tool to Understand the Mode of Action of Novel Anthelmintics; C. elegans as a Platform for Target Discovery; Conclusions; References; 3 Integrating and Mining Helminth Genomes to Discover and Prioritize Novel Therapeutic Targets.
|
505 |
8 |
|
|a Introduction; Availability of Genome Sequence Information for Parasitic Helminths; Overview of Genome Annotation Datasets that Aid Target Identification; Orthology-Based Annotations and Comparative Genomics; Predictions of Essentiality; Orthology-Based RNAi Phenotype Data Mapping Between C. elegans and Parasitic Helminths; The TDR Targets Database; Target Prioritization in B. malayi and S. mansoni Using the TDR Targets Database; Currently Unavailable Genomic Datasets that will Improve Target Prioritization for Parasitic Helminths; Conclusions; Acknowledgments; References.
|
505 |
8 |
|
|a 4 Recent Progress in Transcriptomics of Key Gastrointestinal Nematodes of Animals -- Fundamental Research Toward New Intervention Strategies; Introduction; Recent Developments in the Bioinformatic Tools and Pipelines for the Analysis of Expressed Sequence Tag Data; Characterizing the Transcriptomes of Strongylid Nematodes; Conclusions and Prospects; Acknowledgments; References; 5 Harnessing Genomic Technologies to Explore the Molecular Biology of Liver Flukes-Major Implications for Fundamental and Applied Research; Introduction.
|
520 |
|
|
|a This third volume in the successful 'Drug Discovery in Infectious Diseases' series is the first to deal with drug discovery in helminthic infections in human and animals. The result is a broad overview of different drug target evaluation methods, including specific examples of successful drug development against helminthes, and with a whole section devoted to vaccine development. With its well-balanced mix of high-profile contributors from academia and industry, this handbook and reference will appeal to a wide audience, including parasitologists, pharmaceutical industry, epidemiologists, and.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Anthelmintics
|x Development.
|
650 |
|
0 |
|a Helminthiasis
|x Chemotherapy.
|
650 |
|
6 |
|a Anthelminthiques
|x Développement.
|
650 |
|
6 |
|a Helminthiase
|x Chimiothérapie.
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Helminthiasis
|x Chemotherapy
|2 fast
|
700 |
1 |
|
|a Caffrey, Conor R.
|
700 |
1 |
|
|a Selzer, P. M.
|q (Paul M.)
|1 https://id.oclc.org/worldcat/entity/E39PCjyRPY3YdH4d8Qt86J8P33
|
758 |
|
|
|i has work:
|a Parasitic helminths (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFB8Xcbfh3Vjy7TwVcpF8C
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|a Caffrey, Conor R.
|t Parasitic Helminths.
|d Hoboken : John Wiley & Sons, ©2012
|z 9783527330591
|
830 |
|
0 |
|a Drug discovery in infectious diseases.
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=945185
|z Texto completo
|
938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL945185
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 463084
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 8857278
|
994 |
|
|
|a 92
|b IZTAP
|